ALBERT

Keywords: Boston ; Cardiac Surgical Procedures/*economics ; *Federal Government ; Government Agencies ; Government Regulation ; *Heart Transplantation ; Hospitals, General ; Humans ; *Patient Selection ; *Resource Allocation ; Transplantation, Homologous ; United States

Keywords: *Federal Government ; Humans ; *Medicare ; Quality of Health Care ; Renal Dialysis/economics/rehabilitation/*trends ; Resource Allocation ; United States

Keywords: *Advisory Committees ; Bioethical Issues ; Bioethics ; *Federal Government ; *Government ; Government Regulation ; Politics ; *Public Policy ; Social Control, Formal

Keywords: *Federal Government ; *Government Agencies ; *Government Regulation ; *Health Policy ; Humans ; Occupational Diseases/*prevention & control ; United States

Keywords: *Compensation and Redress ; Costs and Cost Analysis ; Disclosure ; Drug Industry/economics/*standards ; *Federal Government ; Humans ; Insurance ; *Jurisprudence ; Mandatory Programs ; Risk ; Risk Assessment ; United States ; Vaccines/*adverse effects ; Voluntary Programs

Keywords: *Biomedical Research ; *Federal Government ; *Government Regulation ; History, 20th Century ; Humans ; *National Institutes of Health (U.S.) ; Neoplasms ; Politics ; *Research Support as Topic ; United States

Keywords: Amygdalin/*therapeutic use ; *Federal Government ; Humans ; Neoplasms/*drug therapy ; Orthomolecular Therapy

Keywords: *Federal Government ; *Financial Support ; *Financing, Government ; *Fraud ; *Government ; Government Regulation ; *Human Experimentation ; Humans ; Neoplasms ; Pharmaceutical Preparations ; Public Policy ; *Research Personnel ; *Scientific Misconduct ; Social Control, Formal ; Social Responsibility ; United States Dept. of Health and Human Services

Keywords: *Federal Government ; *Fees and Charges ; *Government ; *Government Regulation ; Humans ; Legislation as Topic ; *Social Control, Formal ; *Tissue Donors ; *Tissue and Organ Procurement ; Congress and the Administration to propose a clearinghouse to coordinate donation ; of organs. The Administration is backing a private group for the task, while ; congressional proposals would establish a national clearinghouse, limit ; transplants to hospitals meeting federal criteria, and ban the sale of organs.

Keywords: *Advisory Committees ; *Containment of Biohazards ; *DNA, Recombinant ; *Federal Government ; *Government Regulation ; *National Institutes of Health (U.S.) ; United States

Keywords: *Advisory Committees ; Containment of Biohazards ; *DNA, Recombinant ; *Federal Government ; *Government Regulation ; *National Institutes of Health (U.S.) ; United States ; Health has encountered setbacks in its attempt to increase its regulatory ; authority over genetic engineering ventures. Competing claims by the ; Environmental Protection Agency have been supported in a congressional report ; authored by Rep. Albert Gore, Jr. (D-Tenn.) which is critical of RAC's actions in ; approving experimental release of genetically-modified organisms into the ; environment. During a 6 Feb 1984 public meeting, RAC faced a barrage of criticism ; led by activist Jeremy Rifkin, and learned of a U.S. Court of Appeals decision ; blocking its consideration of a proposed field test with engineered bacteria.

Keywords: *Advisory Committees ; *DNA, Recombinant ; *Federal Government ; *Government Regulation ; *National Institutes of Health (U.S.) ; United States ; Recombinant DNA Advisory Committee (RAC) are seen as potentially detrimental to ; RAC's credibility. Each session was closed on grounds that proprietary data were ; being reviewed. NIH Director James B. Wyngaarden has implemented a formal review ; of the extent of the authority of RAC, which currently reviews not only research ; projects funded by its parent agency but also voluntarily-submitted industrial ; proposals and proposals of other federal government agencies.

Keywords: *Bioethics ; *Federal Government ; *Financial Support ; *Financing, Government ; *Government ; *Public Policy

Keywords: Costs and Cost Analysis ; Cyclosporins/therapeutic use ; *Federal Government ; Resource Allocation ; *Transplantation, Homologous/methods

Keywords: Biomedical Technology ; *Cost-Benefit Analysis ; Ecology ; *Federal Government ; *Government ; *Government Regulation ; Hazardous Substances ; Humans ; Jurisprudence ; Nuclear Energy ; Pharmaceutical Preparations ; *Public Policy ; Risk ; Risk Assessment ; Social Change ; *Social Control, Formal ; *Technology ; *Technology Assessment, Biomedical

Keywords: Advisory Committees ; *DNA, Recombinant ; *Federal Government ; *Government ; *Government Regulation ; Public Policy ; *Social Control, Formal

Keywords: Bioethical Issues ; Ethics ; *Federal Government ; *Infant Food ; *National Institutes of Health (U.S.) ; United States ; discussion of a dispute on the marketing of infant formula from a symposium on ; bioethics because of protests by the Nestle Company. NIH administrators deny that ; censorship was the reason for the cancellation.

Keywords: *Aborted Fetus ; *Federal Government ; *Fetal Research ; *Fetus ; *Government Regulation ; *Human Experimentation ; Humans ; *Infant, Newborn ; *Legislation, Medical ; United States

Keywords: *Containment of Biohazards ; *DNA, Recombinant ; *Federal Government ; Government ; *Government Regulation ; United States ; and the Office of Management and Budget, has convened a working group ; representing 15 federal agencies to discuss the regulation of biotechnology. ; George A. Keyworth, presidential science adviser, asked the agencies to report ; back at the next meeting what jurisdiction they claim in biotechnology ; regulation. The Environmental Protection Agency (EPA) is currently developing a ; proposal on its role. Various other agencies have been discussing federal ; involvement with industry representatives.

Keywords: Advisory Committees ; DNA, Recombinant ; *Federal Government ; *Genetic Engineering ; *Government Regulation ; Industry ; Legislation as Topic ; National Institutes of Health (U.S.) ; United States ; United States Environmental Protection Agency ; engineering industry. Federal officials are aware of the pressing need for a ; comprehensive, coordinated policy that will regulate biotechnology without ; hampering its growth or driving companies abroad. A Cabinet-level working group ; involving 15 agencies and the Environmental Protection Agency plans to issue ; reports in Fall 1984 on the direction federal involvement should take. ; Consideration is being given to expanding the regulatory role of the National ; Institutes of Healths' Recombinant DNA Advisory Committee, even while the ; committee awaits judicial review of its past decisions.

Keywords: *Cyclosporins ; *Federal Government ; Humans ; *Legislation, Drug ; Medicare/*legislation & jurisprudence ; *Resource Allocation ; Transplantation/economics ; United States ; and Means health subcommittee minus the so-called "cyclosporine amendment," a ; provision which would have extended Medicare coverage to the long-term use of ; immunosuppressive drugs for organ transplant recipients. Cyclosporine became a ; focus of dispute because of its high cost. Opponents of the deleted provision ; argued that it would break the precedent under which Medicare pays for drugs only ; while a patient is in the hospital. Committee members report that pressure from ; physicians and patients is building to revive the deleted proposal.

Keywords: *Federal Government ; *Health Policy ; United States ; country without any comprehensive, nonpartisan forum for assessing the safety and ; cost effectiveness of biomedical technologies. While many private and public ; groups found the Center's evaluations useful, the American Medical Association ; and the Health Industry Manufacturers Association viewed it as a regulatory ; agency and lobbied for its closure. Despite the efforts of various medical ; societies, insurers, and the medical device industry to establish their own ; review programs, many policy analysts would like to see a federal panel revived.

Keywords: *DNA, Recombinant ; Ecology ; *Federal Government ; *Government ; *Government Regulation ; Hazardous Substances ; Public Policy ; *Social Control, Formal ; the topic of a 22 June 1983 hearing held by Representatives Albert Gore and Doug ; Walgren. Scientists testified that potential hazards from the release of rDNA ; organisms into the environment are low, and that voluntary guidelines, like those ; of the National Institutes of Health's Recombinant DNA Advisory Committee, are ; sufficient to control the new technology. Some government officials concur with ; this assessment. Should increased federal oversight be decided upon, it has yet ; to be established whether the Environmental Protection Agency or the Agriculture ; Department has regulatory authority.